Therapeutic Asset Ratings

204 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Posiphen Alzheimer Disease	Annovis Bio Inc.	P2/3	B (57)
Choline Alfoscerate Alzheimer Disease	Daewoong Bio Inc.	P4	B (56)
Folic Acid Alzheimer Disease	Wake Forest University Health Sciences	P4	B (56)
Gabapentin Enacarbil Alzheimer Disease	University of Texas at Austin	P4	B (56)
Sodium Oligomannate Alzheimer Disease	First Affiliated Hospital Xi'an Jiaotong University	P4	B (56)
Zinc Alzheimer Disease	Wake Forest University Health Sciences	P4	B (56)
Zunveyl® Alzheimer Disease	Alpha Cognition, Inc	P4	B (56)
ar1001 Alzheimer Disease	AriBio Co., Ltd.	P3	B (56)
CAFFEINE Alzheimer Disease	University Hospital, Lille	P3	B (56)
Enavermotide Alzheimer Disease	Samsung Pharmaceutical Co., Ltd.	P3	B (56)
Keppra Alzheimer Disease	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	P3	B (56)
Masitinib Alzheimer Disease	AB Science	P3	B (56)
Masupirdine Alzheimer Disease	Suven Life Sciences Limited	P3	B (56)
mlc901 Alzheimer Disease	Moleac Pte Ltd.	P3	B (56)
Nilotinib Alzheimer Disease	KeifeRx, LLC	P3	B (56)
Rotigotine Alzheimer Disease	I.R.C.C.S. Fondazione Santa Lucia	P3	B (56)
TROSPIUM Alzheimer Disease	Neurology Office of South Florida	P3	B (56)
Xanomeline Alzheimer Disease	Neurology Office of South Florida	P3	B (56)
Aadvac1 Alzheimer Disease	Paul S. Aisen	P2	CCC (55)
Astrostem Alzheimer Disease	Nature Cell Co. Ltd.	P2	CCC (55)
ER-176 Alzheimer Disease	The Methodist Hospital Research Institute	P2	CCC (55)
FLAVONE, 3,3',4',5,7-PENTAHYDROXY- Alzheimer Disease	Zaparackas and Knepper LTD	P2	CCC (55)
Nicotinamide Ribonucleoside Alzheimer Disease	Mclean Hospital	P2	CCC (55)
al002 Alzheimer Disease	Alector Inc.	P2	CCC (54)
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines. Alzheimer Disease	NKGen Biotech, Inc.	P2	CCC (54)

Showing 26 to 50 of 204 assets

PreviousPage 2 of 9Next